305.61
전일 마감가:
$297.89
열려 있는:
$304.67
하루 거래량:
223.38K
Relative Volume:
0.43
시가총액:
$13.79B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
12.20
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+2.50%
1개월 성능:
+6.71%
6개월 성능:
-17.82%
1년 성능:
-9.24%
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
2024-02-05 | 개시 | Leerink Partners | Outperform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2022-12-06 | 개시 | UBS | Buy |
2022-12-05 | 개시 | Goldman | Sell |
2022-10-11 | 개시 | Morgan Stanley | Overweight |
2022-09-20 | 재확인 | BofA Securities | Underperform |
2022-09-19 | 재개 | Wedbush | Outperform |
2022-02-11 | 개시 | BTIG Research | Neutral |
2021-07-14 | 업그레이드 | Argus | Hold → Buy |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-09-14 | 재개 | JP Morgan | Overweight |
2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-12-03 | 개시 | BofA/Merrill | Underperform |
2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2018-02-22 | 재확인 | Barclays | Underweight |
2018-01-18 | 재개 | Credit Suisse | Underperform |
2017-12-27 | 재확인 | Wedbush | Outperform |
2017-04-27 | 재확인 | Wedbush | Outperform |
2017-03-30 | 개시 | UBS | Sell |
2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - Insider Monkey
What analysts say about United Therapeutics Corporation stockConsistent triple returns - jammulinksnews.com
Is United Therapeutics Corporation a good long term investmentBreakthrough profit margins - jammulinksnews.com
United Therapeutics Corporation Stock Analysis and ForecastAccelerated profit realization - jammulinksnews.com
What drives United Therapeutics Corporation stock priceSkyrocketing investment returns - jammulinksnews.com
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating - Insider Monkey
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
Pulmonary Arterial Hypertension Market Forecast 2034: - openPR.com
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Pulmonary Arterial Hypertension Drug Market Forecast to 2032: - openPR.com
United Therapeutics Announces Q2 Earnings Date: Key Details for Biotech Investment Community - Stock Titan
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $510 - 富途牛牛
Reflecting On Therapeutics Stocks' Q1 Earnings: Moderna (NASDAQ:MRNA) - FinancialContent
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment - Yahoo Finance
United Therapeutics Puts Big Bets On Tyvaso’s Trial Results - Finimize
United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says - MarketScreener
United Therapeutics (UTHR) Awaits Key Catalyst with Positive Ris - GuruFocus
United Therapeutic's: The Brands First Hydrogen Helicopter - Energy Digital Magazine
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors - TipRanks
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - Insider Monkey
United Therapeutics (UTHR) Price Target Adjustment by Morgan Sta - GuruFocus
United Therapeutics (UTHR) Price Target Trimmed by Morgan Stanle - GuruFocus
United Therapeutics' Inhaled Treprostinil Study for Pulmonary Fibrosis: Key Insights for Investors - AInvest
United Therapeutics (UTHR): JP Morgan Adjusts Price Target | UTH - GuruFocus
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lowered by UBS | UTHR Stock News - GuruFocus
United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lo - GuruFocus
United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study - Yahoo Finance
United Therapeutics EVP Mahon sells $3.14 million in UTHR stock - Investing.com
United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment - TipRanks
Nilda Mesa, United Therapeutics director, sells $187k in stock - Investing.com
United Therapeutics (UTHR) Begins Groundbreaking Clinical Study with miroliverELAP | UTHR Stock News - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? - Yahoo Finance
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
United Therapeutics: Tanking On Rival's PAH DataI'd Consider Buying Stock (NASDAQ:UTHR) - Seeking Alpha
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset - Seeking Alpha
Treprostinil Saga Continues - JD Supra
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):